跳转至内容
Merck
CN
所有图片(2)

文件

444966

Sigma-Aldrich

MEK1/2抑制剂III

The MEK1/2 Inhibitor III, also referenced under CAS 391210-10-9, controls the biological activity of MEK1/2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

MEK1/2抑制剂III

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H14F3IN2O4
分子量:
482.19
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

检测方案

≥95% (HPLC)

形式

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

white to off-white

溶解性

DMSO: 20 mg/mL

运输

ambient

储存温度

2-8°C

InChI

1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1

InChI key

SUDAHWBOROXANE-SECBINFHSA-N

一般描述

一种可渗透细胞的苯甲酰胺化合物,可作为非竞争性,高效,选择性MEK/MAPKK/MKK抑制剂,并有效阻断细胞Erk1/2磷酸化(在血清刺激后血清饥饿的HeLa中降低>90%,在C26中降低50%,分别使用25和0.33 nM抑制剂),而在无细胞激酶测定中,即使在浓度为高10 µM的情况下,对Erk1/2或一组66种其他激酶的活性也影响很小或没有影响。显示可在小鼠中口服使用,并在体内抑制表达BRAF(V600E)的SKMEL28细胞源性肿瘤的生长和Erk磷酸化。
一种可渗透细胞的苯甲酰胺化合物,可作为非竞争性,高效,选择性MEK/MAPKK/MKK抑制剂,并有效阻断细胞Erk1/2磷酸化(在血清刺激后血清饥饿的HeLa中降低>90%,在C26中降低50%,分别使用25和0.33 nM抑制剂),而在无细胞激酶测定中,即使在浓度为高10 µM的情况下,对Erk1/2或一组66种其他激酶的活性也影响很小或没有影响。显示可在小鼠中口服使用,并在体内抑制表达BRAF(V600E)的SKMEL28细胞源性肿瘤的生长和Erk磷酸化。也有InSolution 格式(目录号444968)。

包装

用惰性气体包装

警告

毒性:标准处理(A)

重悬

复溶后,等分并冷冻保存(-20°C)。贮备液在-20°C下可稳定保存至多3个月。

其他说明

Barrett, S.D., et al. 2008.Bioorg.Med. Chem. Lett.18, 6501.
Leyton, J., et al. 2008.Mol.Cancer Ther.7, 3112.
Silva, J., et al. 2008.PLoS Biol.6, 2237.
Ying, Q.L., et al. 2008.Nature453, 519.
Bain, J., et al. 2007.Biochem.J.408, 297.
Solit, D.B., et al. 2006.Nature439, 358.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral - Aquatic Chronic 4 - STOT RE 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Phillip Wulfridge et al.
eLife, 10 (2021-02-24)
R-loops are three-stranded nucleic acid structures with essential roles in many nuclear processes. However, their unchecked accumulation is associated with genome instability and is observed in neurodevelopmental diseases and cancers. Genome-wide profiling of R-loops in normal and diseased cells can
Jian Yang et al.
Cell reports, 43(3), 113775-113775 (2024-02-21)
In mammals, many retrotransposons are de-repressed during zygotic genome activation (ZGA). However, their functions in early development remain elusive largely due to the challenge to simultaneously manipulate thousands of retrotransposon insertions in embryos. Here, we applied CRISPR interference (CRISPRi) to
Ana Petracovici et al.
Molecular cell, 81(12), 2625-2639 (2021-04-23)
The Polycomb repressive complex 2 (PRC2) is an essential epigenetic regulator that deposits repressive H3K27me3. PRC2 subunits form two holocomplexes-PRC2.1 and PRC2.2-but the roles of these two PRC2 assemblies during differentiation are unclear. We employed auxin-inducible degradation to deplete PRC2.1
Qingqing Yan et al.
Nature communications, 13(1), 53-53 (2022-01-12)
R-loops are three-stranded nucleic acid structures that accumulate on chromatin in neurological diseases and cancers and contribute to genome instability. Using a proximity-dependent labeling system, we identified distinct classes of proteins that regulate R-loops in vivo through different mechanisms. We
Oriol Iborra-Egea et al.
Methods in molecular biology (Clifton, N.J.), 2454, 61-81 (2021-12-01)
Stem cell therapy has an unparalleled potential to treat blood cancers, cardiovascular diseases and neurodegenerative conditions, among others. However, stem cell therapeutics must overcome multiple requirements before reaching clinical trials, including large animal safety and efficacy studies. In cardiovascular diseases

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门